

Andrew J Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7191725/publications.pdf>

Version: 2024-02-01

7

papers

164

citations

1307594

7

h-index

1720034

7

g-index

9

all docs

9

docs citations

9

times ranked

259

citing authors

#	ARTICLE	IF	CITATIONS
1	Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: InÂvitro and inÂvivo appraisal. European Journal of Medicinal Chemistry, 2021, 209, 112914.	5.5	17
2	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both inÂvitro and inÂvivo trypanocidal efficacy. European Journal of Medicinal Chemistry, 2020, 207, 112849.	5.5	13
3	Development of (6R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5iH-imidazo[2,1-ib][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2018, 61, 2329-2352.	6.4	42
4	Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 207-213.	2.2	22
5	7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-ib][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2017, 60, 4212-4233.	6.4	47
6	Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modelling. Bioorganic and Medicinal Chemistry, 2015, 23, 3796-3808.	3.0	9
7	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. MedChemComm, 2014, 5, 41-46.	3.4	12